https://m2.mtmt.hu/ hun 2026-09-22 03:53 JournalArticle 34039197 VALIDATED true 0 false 2026-09-03T08:28:46.306+0000 2026-09-03T08:27:30.666+0000 2023-06-29T08:27:51.999+0000 true 10069606 Pintér Ibolya Katalin /api/admin/10069606 Admin Pintér Ibolya Katalin (SE_AOK_TranszlációsMedInt_Admin5_PI, admin) true 2026-09-03T09:26:52.618+0000 2026-09-03T09:26:52.618+0000 2023-09-01T16:40:18.151+0000 true 10019966 Tóth Henrietta /api/admin/10019966 Admin Tóth Henrietta (ME admin) true 10019966 2023-10-05T08:30:17.637+0000 true 10080205 Szalóky-Siki Ágnes /api/admin/10080205 Admin Szalóky-Siki Ágnes (SE_KK_Admin5_SZSA, admin) true true false true 24 24 /api/publicationtype/24 PublicationType Folyóiratcikk 1 true 24 JournalArticle true 10000059 Article true 24 24 /api/publicationtype/24 PublicationType Folyóiratcikk 1 true 24 JournalArticle /api/subtype/10000059 Szakcikk SubType Szakcikk (Folyóiratcikk) 101 true 10000059 true 1 /api/category/1 Category Tudományos true 1 Kozma, Gergely Tibor true true /api/journal/4363 REVIEWED VACCINE 0264-410X 1873-2518 1358-8745 true false 4363 false 4363 true 0264-410X 1873-2518 Journal FOREIGN 41 31 4561 4570 4561 10 2023 Funding 2048722 /api/funding/2048722 (2020-1.1.6-JOVO-2021-00013) false true Funding 2048723 /api/funding/2048723 European Union Horizon 2020 projects(825828) false true Funding 2048724 /api/funding/2048724 European Union Horizon 2020 projects(952520) false true true true 2023 true true true false true false GREEN 2026-09-03 true https://doi.org/10.1016/j.vaccine.2023.06.009 96 0 96 91 6 96 96 88 76 92 92 87 87 91 5 0 96 91 96 91 0 8 8 Folyóiratcikk Journal Article 24 95 Könyvrészlet Chapter in Book 25 1 Könyv Book 23 0 Egyéb konferenciaközlemény Conference paper 31 0 Egyéb konferenciakötet Conference proceedings 32 0 Oltalmi formák Protection forms 26 0 Disszertáció Thesis 28 0 Egyéb Miscellaneous 29 0 Alkotás Achievement 22 0 Kutatási adat Research data 33 0 Folyóiratcikk Journal Article 24 0 0 0 Könyvrészlet Chapter in Book 25 0 0 0 Könyv Book 23 0 0 0 Egyéb konferenciaközlemény Conference paper 31 0 0 0 Egyéb konferenciakötet Conference proceedings 32 0 0 0 Oltalmi formák Protection forms 26 0 0 0 Disszertáció Thesis 28 0 0 0 Egyéb Miscellaneous 29 0 0 0 Alkotás Achievement 22 0 0 0 Kutatási adat Research data 33 0 0 0 2023 0 6 6 6 6 2024 0 27 25 27 25 2025 0 43 40 43 40 2026 0 20 20 20 20 D1 false 10075617,10024742 false false false 2023-08-31T16:40:17.456+0000 Elméleti Egészségtudományok Intézete (ME / ETK); Gyakorlati Módszertani és Diagnosztikai Intézet (ME / ETK); Kardiológia Központ - Kardiológiai Tanszék (SE / AOK / K); Repülõ- és Űrorvostani Tanszék (SE / AOK / K); Sportorvostan Tanszék (SE / AOK / K); Transzlációs Medicina Intézet (SE / AOK / I); Városmajori Szív- és Érgyógyászati Klinika (SE / AOK / K) 8 64 7 12 0 true Language 10002 /api/language/10002 Angol Angol English true 2 true PersonAuthorship 109109848 /api/authorship/109109848 Kozma, Gergely Tibor [Kozma, Gergely Tibor (Immunológia, Mole...), szerző] Transzlációs Medicina Intézet (SE / AOK / I) 1 0.083 true false false Author 10024742 /api/author/10024742 Kozma Gergely Tibor (Immunológia, Molekuláris biológia) Kozma Gergely Tibor true 10024742 true Kozma Gergely Tibor true false false AuthorshipType 1 /api/authorshiptype/1 Szerző 0 true 0 true false true PersonAuthorship 109109849 /api/authorship/109109849 Mészáros, Tamás [Mészáros, Tamás (nanomedicina), szerző] Transzlációs Medicina Intézet (SE / AOK / I) 2 0.083 false false false Author 10064003 /api/author/10064003 Mészáros Tamás (nanomedicina) Mészáros Tamás true 10064003 true Mészáros Tamás true false false AuthorshipType 1 /api/authorshiptype/1 Szerző 0 true 0 true false true PersonAuthorship 109109850 /api/authorship/109109850 Berényi, Petra 3 0.083333336 false false false Berényi Petra true false false AuthorshipType 1 /api/authorshiptype/1 Szerző 0 true 0 true false true PersonAuthorship 109109851 /api/authorship/109109851 Facskó, Réka [Facskó, Réka (elméleti orvostud...), szerző] Transzlációs Medicina Intézet (SE / AOK / I) 4 0.083 false false false Author 10083173 /api/author/10083173 Facskó Réka (elméleti orvostudományok) Facskó Réka true true Facskó Réka true false false AuthorshipType 1 /api/authorshiptype/1 Szerző 0 true 0 true false true PersonAuthorship 109109852 /api/authorship/109109852 Patkó, Zsófia [Patkó, Zsófia Panna (farmakokinetika, ...), szerző] Gyakorlati Módszertani és Diagnosztikai Intézet (ME / ETK) 5 0.083 false false false Author 10032791 /api/author/10032791 Patkó Zsófia Panna (farmakokinetika, nukleáris medicina, radiológia) Patkó Zsófia Panna DUPLUM true 10032791 true Patkó Zsófia true false false AuthorshipType 1 /api/authorshiptype/1 Szerző 0 true 0 true false true PersonAuthorship 109109853 /api/authorship/109109853 Oláh, Csaba Zs. [Oláh, Csaba Zsolt (idegsebészet), szerző] 6 0.083333336 false false false Author 10075617 /api/author/10075617 Oláh Csaba Zsolt (idegsebészet) Oláh Csaba Zsolt true true Oláh Csaba Zs. true false false AuthorshipType 1 /api/authorshiptype/1 Szerző 0 true 0 true false true PersonAuthorship 109109854 /api/authorship/109109854 Nagy, Adrienne 7 0.083333336 false false false Nagy Adrienne true false false AuthorshipType 1 /api/authorshiptype/1 Szerző 0 true 0 true false true PersonAuthorship 109109855 /api/authorship/109109855 Fülöp, Tamás Gyula 8 0.083333336 false false false Fülöp Tamás Gyula true false false AuthorshipType 1 /api/authorshiptype/1 Szerző 0 true 0 true false true PersonAuthorship 109109856 /api/authorship/109109856 Glatter, Kathryn Anne 9 0.083333336 false false false Glatter Kathryn Anne true false false AuthorshipType 1 /api/authorshiptype/1 Szerző 0 true 0 true false true PersonAuthorship 109109857 /api/authorship/109109857 Radovits, Tamás [Radovits, Tamás (kardiológia, érgy...), szerző] Városmajori Szív- és Érgyógyászati Klinika (SE / AOK / K); Kardiológia Központ - Kardiológiai Tanszék (SE / AOK / K) 10 0.083 false false false Author 10013969 /api/author/10013969 Radovits Tamás (kardiológia, érgyógyászat) Radovits Tamás true 10013969 true Radovits Tamás true false false AuthorshipType 1 /api/authorshiptype/1 Szerző 0 true 0 true false true PersonAuthorship 109109858 /api/authorship/109109858 Merkely, Béla** [Merkely, Béla Péter (Kardiológia), szerző] Városmajori Szív- és Érgyógyászati Klinika (SE / AOK / K); Kardiológia Központ - Kardiológiai Tanszék (SE / AOK / K); Sportorvostan Tanszék (SE / AOK / K); Repülõ- és Űrorvostani Tanszék (SE / AOK / K) 11 0.083 false true false Author 10002691 /api/author/10002691 Merkely Béla Péter (Kardiológia) Merkely Béla Péter true 10002691 true Merkely Béla true false false AuthorshipType 1 /api/authorshiptype/1 Szerző 0 true 0 true false true PersonAuthorship 109109859 /api/authorship/109109859 Szebeni, János ✉ [Szebeni, János (Klinikai orvostud...), szerző] Elméleti Egészségtudományok Intézete (ME / ETK); Transzlációs Medicina Intézet (SE / AOK / I) 12 0.083 false true true Author 10003266 /api/author/10003266 Szebeni János (Klinikai orvostudomány, immunológia, nanomedicina) Szebeni János true 10003266 true Szebeni János true false false AuthorshipType 1 /api/authorshiptype/1 Szerző 0 true 0 true false true PublicationIdentifier 24096623 /api/publicationidentifier/24096623 DOI: 10.1016/j.vaccine.2023.06.009 PlainSource 6 /api/publicationsource/6 DOI PublicationSourceType 10001 /api/publicationsourcetype/10001 DOI true true true DOI DOI https://doi.org/@@@ true true 6 true GREEN true IDENTICAL 10.1016/j.vaccine.2023.06.009 https://doi.org/10.1016/j.vaccine.2023.06.009 false true PublicationIdentifier 24460678 /api/publicationidentifier/24460678 WoS: 001062152800001 PlainSource 1 /api/publicationsource/1 WoS PublicationSourceType 10003 /api/publicationsourcetype/10003 Indexelő adatbázis false true true WoS WoS https://www.webofscience.com/wos/woscc/full-record/@@@ true true 1 true IDENTICAL 001062152800001 https://www.webofscience.com/wos/woscc/full-record/001062152800001 true true PublicationIdentifier 24180134 /api/publicationidentifier/24180134 Scopus: 85163363171 PlainSource 3 /api/publicationsource/3 Scopus PublicationSourceType 10003 /api/publicationsourcetype/10003 Indexelő adatbázis false true true Scopus Scopus http://www.scopus.com/record/display.url?origin=inward&eid=2-s2.0-@@@ true true 3 true IDENTICAL 85163363171 http://www.scopus.com/record/display.url?origin=inward&eid=2-s2.0-85163363171 true true PublicationIdentifier 24180132 /api/publicationidentifier/24180132 PubMed: 37330369 PlainSource 17 /api/publicationsource/17 PubMed PublicationSourceType 10003 /api/publicationsourcetype/10003 Indexelő adatbázis false true true PubMed PubMed http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=@@@&dopt=Abstract true true 17 true IDENTICAL 37330369 http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=37330369&dopt=Abstract true true SjrRating 11420553 /api/sjrrating/11420553 sjr:D1 (2023) Scopus - Veterinary (miscellaneous) VACCINE 0264-410X 1873-2518 1358-8745 3 0.1 journal RatingType 10002 /api/ratingtype/10002 sjr sjr true true ClassificationExternal 3401 /api/classificationexternal/3401 Scopus - Veterinary (miscellaneous) true 3401 true D1 DIRECT true true Reference 43026081 /api/reference/43026081 1. Fraiman 2022: Serious adverse events of special interest following mRNA COVID-19 vaccination in randomized trials in adults., Vaccine, 40, p. 5798, DOI: 10.1016/j.vaccine.2022.08.036 1 10.1016/j.vaccine.2022.08.036 false true Reference 43026082 /api/reference/43026082 2. Banerji 2020: mRNA vaccines to prevent COVID-19 disease and reported allergic reactions: Current evidence and suggested approach., J Allergy Clin Immunol Pract 2 false true Reference 43026083 /api/reference/43026083 3. Warren 2021: Assessment of allergic and anaphylactic reactions to mRNA COVID-19 vaccines with confirmatory testing in a US regional health system., JAMA Netw Open, 4, DOI: 10.1001/jamanetworkopen.2021.25524 3 10.1001/jamanetworkopen.2021.25524 false true Reference 43026084 /api/reference/43026084 4. Shimabukuro 2021: Allergic reactions including anaphylaxis after receipt of the first dose of Moderna COVID-19 vaccine - United States, December 21, 2020-January 10, 2021., Am J Transplant, 21, p. 1326, DOI: 10.1111/ajt.16517 4 10.1111/ajt.16517 false true Reference 43026085 /api/reference/43026085 5. Shimabukuro 2021: Allergic reactions including anaphylaxis after receipt of the first dose of Pfizer-BioNTech COVID-19 vaccine., JAMA, DOI: 10.1001/jama.2021.0600 5 10.1001/jama.2021.0600 false true Reference 43026086 /api/reference/43026086 6. Kounis 2021: Allergic reactions to current available COVID-19 vaccinations., Pathophysiol, Causality, Therap Considerations Vaccines (Basel), 9 6 false true Reference 43026087 /api/reference/43026087 7. Lim 2021: Pseudo-anaphylactic reactions to Pfizer BNT162b2 vaccine: Report of 3 cases of anaphylaxis post Pfizer BNT162b2 vaccination., Vaccines (Basel), 9 7 false true Reference 43026088 /api/reference/43026088 8. Krantz 2021: Anaphylaxis to the first dose of mRNA SARS-CoV-2 vaccines: Don't give up on the second dose!., Allergy, 76, p. 2916, DOI: 10.1111/all.14958 8 10.1111/all.14958 false true Reference 43026089 /api/reference/43026089 9. Blumenthal 2021: Acute allergic reactions to mRNA COVID-19 vaccines., JAMA, 325, p. 1562, DOI: 10.1001/jama.2021.3976 9 10.1001/jama.2021.3976 false true Reference 43026090 /api/reference/43026090 10. Nittner-Marszalska 2021: Pfizer-BioNTech COVID-19 vaccine tolerance in allergic versus non-allergic individuals., Vaccines (Basel), 9 10 false true Reference 43026091 /api/reference/43026091 11. Shavit 2021: Prevalence of allergic reactions after Pfizer-BioNTech COVID-19 vaccination among adults with high allergy risk., JAMA Netw Open, 4, DOI: 10.1001/jamanetworkopen.2021.22255 11 10.1001/jamanetworkopen.2021.22255 false true Reference 43026092 /api/reference/43026092 12. Gringeri 2021: Preliminary evidence on the safety profile of BNT162b2 (Comirnaty): new insights from data analysis in EudraVigilance and adverse reaction reports from an Italian health facility., Hum Vaccin Immunother, 17, p. 2969, DOI: 10.1080/21645515.2021.1917236 12 10.1080/21645515.2021.1917236 false true Reference 43026093 /api/reference/43026093 13. Risma 2021: Potential mechanisms of anaphylaxis to COVID-19 mRNA vaccines., J Allergy Clin Immunol, DOI: 10.1016/j.jaci.2021.04.002 13 10.1016/j.jaci.2021.04.002 false true Reference 43026094 /api/reference/43026094 14. McSweeney 2021: Anaphylaxis to Pfizer/BioNTech mRNA COVID-19 vaccine in a patient with clinically confirmed PEG allergy., Front Allergy, 2, DOI: 10.3389/falgy.2021.715844 14 10.3389/falgy.2021.715844 false true Reference 43026095 /api/reference/43026095 15. Wolfson 2021: First-dose mRNA COVID-19 vaccine allergic reactions: Limited role for excipient skin testing., J Allergy Clin Immunol Pract, 9, p. 3308, DOI: 10.1016/j.jaip.2021.06.010 15 10.1016/j.jaip.2021.06.010 false true Reference 43026096 /api/reference/43026096 16. Luxi 2022: Allergic reactions to COVID-19 vaccines: Risk factors, frequency, mechanisms and management., BioDrugs, 36, p. 443, DOI: 10.1007/s40259-022-00536-8 16 10.1007/s40259-022-00536-8 false true Reference 43026097 /api/reference/43026097 17. Szebeni 2022: Applying lessons learned from nanomedicines to understand rare hypersensitivity reactions to mRNA-based SARS-CoV-2 vaccines., Nat Nanotechnol, 17, p. 337, DOI: 10.1038/s41565-022-01071-x 17 10.1038/s41565-022-01071-x false true Reference 43026098 /api/reference/43026098 18. Anis 2022: Reporting of allergic reactions during Pfizer-BioNTech BNTT162B2 vaccination in Israel., J Allergy Clin Immunol Pract, DOI: 10.1016/j.jaip.2022.07.012 18 10.1016/j.jaip.2022.07.012 false true Reference 43026099 /api/reference/43026099 19. Pfizer Responds to Research Claims. Press release on January 27, 2023 - 08:00pm. https://wwwpfizercom/news/announcements/pfizer-responds-research-claims; 2023. 19 false true Reference 43026100 /api/reference/43026100 20. Garvey 2020: Anaphylaxis to the first COVID-19 vaccine: is polyethylene glycol (PEG) the culprit?., Br J Anesthesia 20 false true Reference 43026101 /api/reference/43026101 21. Vrieze 2020: Suspicions grow that nanoparticles in Pfizer’s COVID-19 vaccine trigger rare allergic reactions., Science 21 false true Reference 43026102 /api/reference/43026102 22. Sellaturay 2021: Polyethylene glycol (PEG) is a cause of anaphylaxis to the Pfizer/BioNTech mRNA COVID-19 vaccine., Clin Exp Allergy, 51, p. 861, DOI: 10.1111/cea.13874 22 10.1111/cea.13874 false true Reference 43026103 /api/reference/43026103 23. Ju 2022: Anti-PEG antibodies boosted in humans by SARS-CoV-2 lipid nanoparticle mRNA vaccine., ACS Nano, DOI: 10.1021/acsnano.2c04543 23 10.1021/acsnano.2c04543 false true Reference 43026104 /api/reference/43026104 24. Carreno 2022: mRNA-1273 but not BNT162b2 induces antibodies against polyethylene glycol (PEG) contained in mRNA-based vaccine formulations., Vaccine 24 false true Reference 43026105 /api/reference/43026105 25. Wang H, Wang Y, Yuan C, Xu X, Zhou W, Huang Y, et al. Polyethylene glycol (PEG)-associated immune responses triggered by clinically relevant lipid nanoparticles. 2023: 2022.11.24.516986., DOI: 10.1101/2022.11.24.516986 25 10.1101/2022.11.24.516986 false true Reference 43026106 /api/reference/43026106 26. Chen 2020: Premature drug release from polyethylene glycol (PEG)-coated liposomal doxorubicin via formation of the membrane attack complex., ACS Nano 26 false true Reference 43026107 /api/reference/43026107 27. Estape Senti 2021: Anti-PEG antibodies compromise the integrity of PEGylated lipid-based nanoparticles via complement., J Control Release, 341, p. 475, DOI: 10.1016/j.jconrel.2021.11.042 27 10.1016/j.jconrel.2021.11.042 false true Reference 43026108 /api/reference/43026108 28. Ishida 2008: Accelerated blood clearance (ABC) phenomenon upon repeated injection of PEGylated liposomes., Int J Pharm, 354, p. 56, DOI: 10.1016/j.ijpharm.2007.11.005 28 10.1016/j.ijpharm.2007.11.005 false true Reference 43026109 /api/reference/43026109 29. Abu Lila 2018: Accelerated blood clearance phenomenon and complement activation-related pseudoallergy: Two sides of the same coin.Immune effects of biopharmaceuticals and nanomedicines, p. 771 29 false true Reference 43026110 /api/reference/43026110 30. Hershfield 2014: Induced and pre-existing anti-polyethylene glycol antibody in a trial of every 3-week dosing of pegloticase for refractory gout, including in organ transplant recipients., Arthritis Res Ther, 16, DOI: 10.1186/ar4500 30 10.1186/ar4500 false true Reference 43026111 /api/reference/43026111 31. Calabrese 2017: Frequency, distribution and immunologic nature of infusion reactions in subjects receiving pegloticase for chronic refractory gout., Arthritis Res Ther, 19, DOI: 10.1186/s13075-017-1396-8 31 10.1186/s13075-017-1396-8 false true Reference 43026112 /api/reference/43026112 32. Ganson 2016: Pre-existing anti-polyethylene glycol antibody linked to first-exposure allergic reactions to pegnivacogin, a PEGylated RNA aptamer., J Allergy Clin Immunol, 137, p. 1610, DOI: 10.1016/j.jaci.2015.10.034 32 10.1016/j.jaci.2015.10.034 false true Reference 43026113 /api/reference/43026113 33. Povsic 2016: Pre-existing anti-PEG antibodies are associated with severe immediate allergic reactions to pegnivacogin, a PEGylated aptamer., J Allergy Clin Immunol, 138, p. 1712, DOI: 10.1016/j.jaci.2016.04.058 33 10.1016/j.jaci.2016.04.058 false true Reference 43026114 /api/reference/43026114 34. Okada 2023: Clinical impact of antipolyethylene glycol (PEG) antibody in hematological patients administered PEGylated-granulocyte colony-stimulating factor., Clin Pharmacol Drug Dev, DOI: 10.1002/cpdd.1225 34 10.1002/cpdd.1225 false true Reference 43026115 /api/reference/43026115 35. Kozma 2019: Pseudo-anaphylaxis to polyethylene glycol (PEG)-coated liposomes: Roles of anti-PEG IgM and complement activation in a porcine model of human infusion reactions., ACS Nano, 13, p. 9315, DOI: 10.1021/acsnano.9b03942 35 10.1021/acsnano.9b03942 false true Reference 43026116 /api/reference/43026116 36. Neumann 2021: Development of SARS-CoV-2 specific IgG and virus-neutralizing antibodies after infection with variants of concern or vaccination., Vaccines (Basel), DOI: 10.3390/vaccines9070700 36 10.3390/vaccines9070700 false true Reference 43026117 /api/reference/43026117 37. Rose 2022: Humoral immune response after different SARS-CoV-2 vaccination regimens., BMC Med, 20, DOI: 10.1186/s12916-021-02231-x 37 10.1186/s12916-021-02231-x false true Reference 43026118 /api/reference/43026118 38. Kozma 2020: Anti-PEG antibodies: Properties, formation, testing and role in adverse immune reactions to PEGylated nano-biopharmaceuticals., Adv Drug Deliv Rev, 154–155, p. 163, DOI: 10.1016/j.addr.2020.07.024 38 10.1016/j.addr.2020.07.024 false true Reference 43026119 /api/reference/43026119 39. Dezsi 2022: A naturally hypersensitive porcine model may help understand the mechanism of COVID-19 mRNA vaccine-induced rare (pseudo) allergic reactions: complement activation as a possible contributing factor., Geroscience., 44, p. 597, DOI: 10.1007/s11357-021-00495-y 39 10.1007/s11357-021-00495-y false true Reference 43026120 /api/reference/43026120 40. Roederer 2001: Probability binning comparison: a metric for quantitating multivariate distribution differences., Cytometry, 45, p. 47, DOI: 10.1002/1097-0320(20010901)45:1&lt;47::AID-CYTO1143&gt;3.0.CO;2-A 40 10.1002/1097-0320(20010901)45:1&lt;47::AID-CYTO1143&gt;3.0.CO;2-A false true Reference 43026121 /api/reference/43026121 41. Ruggeberg 2007: Anaphylaxis: case definition and guidelines for data collection, analysis, and presentation of immunization safety data., Vaccine, 25, p. 5675, DOI: 10.1016/j.vaccine.2007.02.064 41 10.1016/j.vaccine.2007.02.064 false true Reference 43026122 /api/reference/43026122 42. Bardenheier 2016: Adverse events following pandemic influenza A (H1N1) 2009 monovalent and seasonal influenza vaccinations during the 2009–2010 season in the active component U.S. military and civilians aged 17–44years reported to the Vaccine Adverse Event Reporting System., Vaccine, 34, p. 4406, DOI: 10.1016/j.vaccine.2016.07.019 42 10.1016/j.vaccine.2016.07.019 false true Reference 43026123 /api/reference/43026123 43. Food and Drug Administration 2021: Allergic reactions including anaphylaxis after receipt of the first dose of moderna COVID-19 vaccine - United States, December 21, 2020-January 10, 2021., MMWR Morb Mortal Wkly Rep, 70, p. 125, DOI: 10.15585/mmwr.mm7004e1 43 10.15585/mmwr.mm7004e1 false true Reference 43026124 /api/reference/43026124 44. Our-World-In-Data Internet link. Covid-vaccine-doses-by-manufacturer. https://ourworldindataorg/grapher/covid-vaccine-doses-by-manufacturer; 2023. 44 false true Reference 43026125 /api/reference/43026125 45. Armstrong JK. The occurrence, induction, specificity and potential effect of antibodies against poly(ethylene glycol). In: Veronese FM, editor. PEGylated protein drugs: Basic science and clinical applications. Birkhäuser Verlag/Switzerland; 2009. p. 147-68., DOI: 10.1007/978-3-7643-8679-5_9 45 10.1007/978-3-7643-8679-5_9 false true Reference 43026126 /api/reference/43026126 46. Garay 2012: Antibodies against polyethylene glycol in healthy subjects and in patients treated with PEG-conjugated agents., Expert Opin Drug Deliv, 9, p. 1319, DOI: 10.1517/17425247.2012.720969 46 10.1517/17425247.2012.720969 false true Reference 43026127 /api/reference/43026127 47. Chen 2016: Measurement of pre-existing IgG and IgM antibodies against polyethylene glycol in healthy individuals., Anal Chem, 88, p. 10661, DOI: 10.1021/acs.analchem.6b03109 47 10.1021/acs.analchem.6b03109 false true Reference 43026128 /api/reference/43026128 48. Lubich 2016: The mystery of antibodies against polyethylene glycol (PEG) - what do we know?., Pharm Res, 33, p. 2239, DOI: 10.1007/s11095-016-1961-x 48 10.1007/s11095-016-1961-x false true Reference 43026129 /api/reference/43026129 49. Chen 2021: Polyethylene glycol immunogenicity: Theoretical, clinical, and practical aspects of anti-polyethylene glycol antibodies., ACS Nano, 15, p. 14022, DOI: 10.1021/acsnano.1c05922 49 10.1021/acsnano.1c05922 false true Reference 43026130 /api/reference/43026130 50. Bavli 2023: Anti-PEG antibodies before and after a first dose of Comirnaty(R) (mRNA-LNP-based SARS-CoV-2 vaccine)., J Control Release, 354, p. 316, DOI: 10.1016/j.jconrel.2022.12.039 50 10.1016/j.jconrel.2022.12.039 false true Reference 43026131 /api/reference/43026131 51. The allergist. Medications containing PEG/Polysorbate. The allergist; 2021 https://theallergist.wordpress.com/2021/03/02/medications-containing-peg-polysorbate/. 51 false true Reference 43026132 /api/reference/43026132 52. Ibrahim 2023: Investigation of anti-PEG antibody response to PEG-containing cosmetic products in mice., J Control Release, 354, p. 260, DOI: 10.1016/j.jconrel.2023.01.012 52 10.1016/j.jconrel.2023.01.012 false true Reference 43026133 /api/reference/43026133 53. Nin-Valencia 2022: Safe administration of SARS-CoV-2 vaccine after desensitization to a biologic containing polysorbate 80 in a patient with polyethylene glycol-induced severe anaphylaxis and sensitization to polysorbate 80., J Investig Allergol Clin Immunol, 0 53 false true Reference 43026134 /api/reference/43026134 54. Li 2022: Macromolecules in polysorbate 80 for injection: an important cause of anaphylactoid reactions., BMC Pharmacol Toxicol, 23, DOI: 10.1186/s40360-022-00591-5 54 10.1186/s40360-022-00591-5 false true Reference 43026135 /api/reference/43026135 55. Drugs.com. Polysorbate-80. https://wwwdrugscom/inactive/polysorbate-80-372html#ref1; 2022. 55 false true Reference 43026136 /api/reference/43026136 56. Gabizon 2020: Complement activation: A potential threat on the safety of poly(ethylene glycol)-coated nanomedicines., ACS Nano, 14, p. 7682, DOI: 10.1021/acsnano.0c03648 56 10.1021/acsnano.0c03648 false true Reference 43026137 /api/reference/43026137 57. FDA 2021: Allergic reactions including anaphylaxis after receipt of the first dose of Pfizer-BioNTech COVID-19 vaccine - United States, December 14–23, 2020., MMWR Morb Mortal Wkly Rep, 70, p. 46, DOI: 10.15585/mmwr.mm7002e1 57 10.15585/mmwr.mm7002e1 false true /api/publication/34039197 Kozma Gergely Tibor et al. Role of anti-polyethylene glycol (PEG) antibodies in the allergic reactions to PEG-containing Covid-19 vaccines: Evidence for immunogenicity of PEG. (2023) VACCINE 0264-410X 1873-2518 1358-8745 41 31 4561-4570<div class="JournalArticle Publication long-list"> <div class="authors"> <img title="Forrásközlemény" style="float: left" src="/frontend/resources/grid/publication-core-icon.png"> <img title="Idézőközlemény" style="float: left" src="/frontend/resources/grid/publication-citation-icon.png"> <div class="autype autype0"> <span class="author-name" mtid="10024742"><a href="/gui2/?type=authors&mode=browse&sel=10024742" target="_blank">Kozma Gergely Tibor (<span class="authorship-author-name">Kozma Gergely Tibor</span> <span class="authorAux-mtmt"> Immunológia, Molekuláris biológia</span>) </a> </span> <span class="author-affil"><span title="Semmelweis Egyetem">SE</span>/<span title="Általános Orvostudományi Kar">AOK</span>/<span title="Intézet">I</span>/Transzlációs Medicina Intézet</span> ;&nbsp;&nbsp;&nbsp; <span class="author-name" mtid="10064003"><a href="/gui2/?type=authors&mode=browse&sel=10064003" target="_blank">Mészáros Tamás (<span class="authorship-author-name">Mészáros Tamás</span> <span class="authorAux-mtmt"> nanomedicina</span>) </a> </span> <span class="author-affil"><span title="Semmelweis Egyetem">SE</span>/<span title="Általános Orvostudományi Kar">AOK</span>/<span title="Intézet">I</span>/Transzlációs Medicina Intézet</span> ;&nbsp;&nbsp;&nbsp; <span class="author-name" >Berényi Petra </span> ;&nbsp;&nbsp;&nbsp; <span class="author-name" mtid="10083173"><a href="/gui2/?type=authors&mode=browse&sel=10083173" target="_blank">Facskó Réka (<span class="authorship-author-name">Facskó Réka</span> <span class="authorAux-mtmt"> elméleti orvostudományok</span>) </a> </span> <span class="author-affil"><span title="Semmelweis Egyetem">SE</span>/<span title="Általános Orvostudományi Kar">AOK</span>/<span title="Intézet">I</span>/Transzlációs Medicina Intézet</span> ;&nbsp;&nbsp;&nbsp; <span class="author-name" mtid="10032791"><a href="/gui2/?type=authors&mode=browse&sel=10032791" target="_blank">Patkó Zsófia (<span class="authorship-author-name">Patkó Zsófia Panna</span> <span class="authorAux-mtmt"> farmakokinetika, nukleáris medicina, radiológia</span>) </a> </span> <span class="author-affil"><span title="Miskolci Egyetem">ME</span>/<span title="Egészségtudományi Kar ">ETK</span>/Gyakorlati Módszertani és Diagnosztikai Intézet</span> ;&nbsp;&nbsp;&nbsp; <span class="author-name" mtid="10075617"><a href="/gui2/?type=authors&mode=browse&sel=10075617" target="_blank">Oláh Csaba Zs. (<span class="authorship-author-name">Oláh Csaba Zsolt</span> <span class="authorAux-mtmt"> idegsebészet</span>) </a> </span> ;&nbsp;&nbsp;&nbsp; <span class="author-name" >Nagy Adrienne </span> ;&nbsp;&nbsp;&nbsp; <span class="author-name" >Fülöp Tamás Gyula </span> ;&nbsp;&nbsp;&nbsp; <span class="author-name" >Glatter Kathryn Anne </span> ;&nbsp;&nbsp;&nbsp; <span class="author-name" mtid="10013969"><a href="/gui2/?type=authors&mode=browse&sel=10013969" target="_blank">Radovits Tamás (<span class="authorship-author-name">Radovits Tamás</span> <span class="authorAux-mtmt"> kardiológia, érgyógyászat</span>) </a> </span> <span class="author-affil"><span title="Semmelweis Egyetem">SE</span>/<span title="Általános Orvostudományi Kar">AOK</span>/<span title="Klinikum">K</span>/Városmajori Szív- és Érgyógyászati Klinika; <span title="Semmelweis Egyetem">SE</span>/<span title="Általános Orvostudományi Kar">AOK</span>/<span title="Klinikum">K</span>/<span title="Városmajori Szív- és Érgyógyászati Klinika">VAROSMAJOR_SZÍVÉRGYÓGY</span>/Kardiológia Központ - Kardiológiai Tanszék</span> ;&nbsp;&nbsp;&nbsp; <span class="author-name" mtid="10002691"><a href="/gui2/?type=authors&mode=browse&sel=10002691" target="_blank">Merkely Béla^** (<span class="authorship-author-name">Merkely Béla Péter</span> <span class="authorAux-mtmt"> Kardiológia</span>) </a> </span> <span class="author-affil"><span title="Semmelweis Egyetem">SE</span>/<span title="Általános Orvostudományi Kar">AOK</span>/<span title="Klinikum">K</span>/Városmajori Szív- és Érgyógyászati Klinika; <span title="Semmelweis Egyetem">SE</span>/<span title="Általános Orvostudományi Kar">AOK</span>/<span title="Klinikum">K</span>/<span title="Városmajori Szív- és Érgyógyászati Klinika">VAROSMAJOR_SZÍVÉRGYÓGY</span>/Kardiológia Központ - Kardiológiai Tanszék; <span title="Semmelweis Egyetem">SE</span>/<span title="Általános Orvostudományi Kar">AOK</span>/<span title="Klinikum">K</span>/<span title="Városmajori Szív- és Érgyógyászati Klinika">VAROSMAJOR_SZÍVÉRGYÓGY</span>/Sportorvostan Tanszék; <span title="Semmelweis Egyetem">SE</span>/<span title="Általános Orvostudományi Kar">AOK</span>/<span title="Klinikum">K</span>/<span title="Városmajori Szív- és Érgyógyászati Klinika">VAROSMAJOR_SZÍVÉRGYÓGY</span>/Repülõ- és Űrorvostani Tanszék</span> ;&nbsp;&nbsp;&nbsp; <span class="author-name" mtid="10003266"><a href="/gui2/?type=authors&mode=browse&sel=10003266" target="_blank">Szebeni János ✉ (<span class="authorship-author-name">Szebeni János</span> <span class="authorAux-mtmt"> Klinikai orvostudomány, immunológia, nanomedicina</span>) </a> </span> <span class="author-affil"><span title="Miskolci Egyetem">ME</span>/<span title="Egészségtudományi Kar ">ETK</span>/Elméleti Egészségtudományok Intézete; <span title="Semmelweis Egyetem">SE</span>/<span title="Általános Orvostudományi Kar">AOK</span>/<span title="Intézet">I</span>/Transzlációs Medicina Intézet</span> </div> </div> <div class="title"><a href="/gui2/?mode=browse&params=publication;34039197" target="_blank">Role of anti-polyethylene glycol (PEG) antibodies in the allergic reactions to PEG-containing Covid-19 vaccines: Evidence for immunogenicity of PEG</a></div> <div> <span class="journal-title">VACCINE</span> <span class="journal-issn">(<a target="_blank" href="https://portal.issn.org/resource/ISSN/0264-410X">0264-410X</a> <a target="_blank" href="https://portal.issn.org/resource/ISSN/1873-2518">1873-2518</a>)</span>: <span class="journal-volume">41</span> <span class="journal-issue">31</span> <span class="page"> pp 4561-4570 </span> <span class="year">(2023)</span> </div> <div class="pub-footer"> <span class="language" xmlns="http://www.w3.org/1999/html">Nyelv: Angol | </span> <span class="identifiers"> <span class="id identifier oa_GREEN" title=" Green "> <a style="color:blue" title="10.1016/j.vaccine.2023.06.009" target="_blank" href="https://doi.org/10.1016/j.vaccine.2023.06.009"> DOI </a> </span> <span class="id identifier oa_none" title="none"> <a style="color:blue" title="001062152800001" target="_blank" href="https://www.webofscience.com/wos/woscc/full-record/001062152800001"> WoS </a> </span> <span class="id identifier oa_none" title="none"> <a style="color:blue" title="85163363171" target="_blank" href="http://www.scopus.com/record/display.url?origin=inward&eid=2-s2.0-85163363171"> Scopus </a> </span> <span class="id identifier oa_none" title="none"> <a style="color:blue" title="37330369" target="_blank" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=37330369&dopt=Abstract"> PubMed </a> </span> </span> <OnlyViewableByAuthor><div class="ratings"> <div class="journal-subject">Folyóirat szakterülete: Scopus - Veterinary (miscellaneous)&nbsp;&nbsp;&nbsp;SJR indikátor:&nbsp;D1</div> <div class="journal-subject">Folyóirat szakterülete: Scopus - Immunology and Microbiology (miscellaneous)&nbsp;&nbsp;&nbsp;SJR indikátor:&nbsp;Q1</div> <div class="journal-subject">Folyóirat szakterülete: Scopus - Infectious Diseases&nbsp;&nbsp;&nbsp;SJR indikátor:&nbsp;Q1</div> <div class="journal-subject">Folyóirat szakterülete: Scopus - Molecular Medicine&nbsp;&nbsp;&nbsp;SJR indikátor:&nbsp;Q1</div> <div class="journal-subject">Folyóirat szakterülete: Scopus - Public Health, Environmental and Occupational Health&nbsp;&nbsp;&nbsp;SJR indikátor:&nbsp;Q1</div> </div></OnlyViewableByAuthor> <div class="publication-citation" style="margin-left: 0.5cm;"> <span title="Nyilvános idézőközlemények összesen, említések nélkül" class="citingPub-count">Nyilvános idéző összesen: 96</span> | Független: 91 | Függő: 5 | Nem jelölt: 0 | WoS jelölt: 88 | Scopus jelölt:&nbsp;76 | WoS/Scopus jelölt:&nbsp;92 | DOI jelölt:&nbsp;96 </div> <div class="publication-citation"> <a target="_blank" href="/api/publication?cond=citations.related;eq;34039197&sort=publishedYear,desc&sort=title"> Idézett közlemények száma: 8 </a> </div> <div class="mtid"><span class="long-pub-mtid">Közlemény: 34039197</span> | <span class="status-data status-VALIDATED"> Egyeztetett </span> Forrás Idéző | <span class="type-subtype">Folyóiratcikk ( Szakcikk ) </span> | <span class="pub-category">Tudományos</span> | <span class="publication-sourceOfData">kézi felvitel</span> </div> <div class="funder"> (2020-1.1.6-JOVO-2021-00013), European Union Horizon 2020 projects(825828), European Union Horizon 2020 projects(952520) </div> <div class="lastModified">Utolsó módosítás: 2026.09.03. 10:27 Milánkovics Róbert (PTE ÁOK admin 4) </div> </div></div>